Table 2 |
||||||
|
Results: P. aeruginosa clinical and microbiologic success, baseline and emergent resistance rates* |
||||||
|
First author, year |
Study arm |
PA isolates (n) |
Clinical success (%) |
Microbiologic eradication (%) |
Resistance at baseline (%) |
Emergent resistance (%) |
|
|
||||||
|
Chastre, 2008 [39] |
Imipenem |
25 |
42.9 |
35.7 |
24.0 |
52.6 |
|
Comparator |
28 |
80.0 |
65.0 |
0.0 |
35.7 |
|
|
Yanagihara, 2005 [40] |
Imipenem |
4 |
50.0 |
|||
|
Comparator |
3 |
0.0 |
||||
|
Joshi, 2006 [42] |
Imipenem |
17 |
70.6 |
|||
|
Comparator |
18 |
76.5 |
||||
|
Romanelli, 2006 [43] |
Imipenem |
1 |
0.0 |
0.0 |
||
|
Comparator |
1 |
0.0 |
0.0 |
|||
|
Shorr, 2005 [44] |
Imipenem |
18† |
72.0 |
5.6 |
||
|
Comparator |
16 |
85.0 |
6.3 |
|||
|
Zanetti, 2003 [45] |
Imipenem |
32 |
15.6 |
28.1 |
||
|
Comparator |
27 |
7.4 |
11.1 |
|||
|
West, 2003 [46] |
Imipenem |
17† |
41.2 |
29.4 |
||
|
Comparator |
17 |
64.7 |
58.8 |
|||
|
Torres, 2000 [47] |
Imipenem |
12 |
66.0 |
25.0 |
33.0 |
|
|
Comparator |
14 |
71.0 |
50.0 |
7.0 |
||
|
Bartoloni, 1999 [48] |
Imipenem |
3 |
66.6 |
66.7 |
||
|
Comparator |
1 |
100.0 |
100.0 |
|||
|
Jaccard, 1998 [49] |
Imipenem |
24 |
50.0 |
4.2 |
25.0 |
|
|
Comparator |
21 |
90.5 |
0.0 |
4.8 |
||
|
Ho, 1997 [51] |
Imipenem |
2 |
50.0 |
|||
|
Comparator |
3 |
100.0 |
||||
|
Raad, 1996 [52] |
Imipenem |
1 |
0.0 |
|||
|
Comparator |
4 |
75.0 |
||||
|
Vic, 1996 [53] |
Imipenem |
1 |
100.0 |
|||
|
Comparator |
19 |
100.0 |
||||
|
Bohme, 1995 [54] |
Imipenem |
3 |
66.0 |
66.0 |
||
|
Comparator |
0 |
NA |
NA |
|||
|
Siami, 1995 [55] |
Imipenem |
9 |
77.8 |
|||
|
Comparator |
12 |
41.7 |
||||
|
Cometta, 1994 [56] |
Imipenem |
24 |
55.6 |
33.3 |
||
|
Comparator |
23 |
50.0 |
56.5 |
|||
|
Fink, 1994 [57] |
Imipenem |
44 |
25.0 |
50.0 |
||
|
Comparator |
47 |
27.7 |
28.0 |
|||
|
Norrby, 1993 [58] |
Imipenem |
14 |
42.1 |
42.9 |
||
|
Comparator |
16 |
82.4 |
6.3 |
|||
|
Pooled rates |
Imipenem |
251 |
45.2 |
47.6 |
14.6 |
38.7 |
|
Comparator |
270 |
74.9 |
52.8 |
2.5 |
21.9 |
|
|
|
||||||
|
*Limited to studies reporting at least one of these outcomes; empty cells indicate that the corresponding data were not reported †Although the total pseudomonal isolates in the two arms of each analysis add up to the same number (n = 34), the distribution between the arms is different presumably due to reclassification of a single PA isolate from the levofloxacin to the imipenem arm, which occurred between the West [46] publication and the Shorr [44] analysis. PA:Pseudomonas aeruginosa; NA: not applicable |
||||||
|
Zilberberg et al. BMC Pulmonary Medicine 2010 10:45 doi:10.1186/1471-2466-10-45 |
||||||
